- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04074993
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10408
- National Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant(or legally acceptable representative if applicable) provides written informed consent for the study
- Patients who have disease progression with prior one ALK-TKI treatment for inoperable Stage III (locally advanced) or metastatic ALK+ NSCLC.(Previous treatment only allowed one ALK-inhibitor) Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle.
- ALK rearrangement , as detected via the blood somatic mutation assay
- One prior ALK inhibitor therapy
- Have at least 1 measurable lesion per RECIST version 1.1
- Have Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Recovered from toxicities related to prior anticancer therapy to NCI CTCAE, version 5.0, Grade≤1(Note : Alopecia, sensory neuropathy Grade≤2, or other Grade≤2 AEs not constituting a safety risk based on Investigator's judgement are acceptable
- Have a life expectancy of ≥3 months
Have adequate organ and hematologic function as determined by:
- ALT/AST≤2.5×ULN; ≤5×ULN is acceptable if liver metastases are present
- Total serum bilirubin≤1.5×ULN (<3.0×ULN for patients with Gilbert syndrome)
- Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, using the MDRD equation
- Absolute neutrophil count ≥1.5×109/L.
- Platelet count ≥75×109/L.
- Hemoglobin ≥9 g/dL.
- Serum lipase ≤1.5×ULN
For female patients of childbearing potential, have a negative pregnancy test(urine or serum) documented ≤3 days before start of study medication.
non-childbearing potential which is defined as :
- female patient≥45 years of age and has not had menses for greater than 1 year
- a female who is status post hysterectomy, oophorectomy
Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourseHave the willingness and ability to comply with scheduled visit and study procedures.
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:
- Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
- Agree to completely abstain from heterosexual intercourse
- Have the willingness and ability to comply with scheduled visit and study procedures.
- Be ≥ 18 years of age
Exclusion Criteria:
- Has received ALK-targeted TKI within 7 days before the first dose of study treatment(If clinically justified, 3 days wash-out period could be allowed).
- Has received radiotherapy within 14 days before the first dose of study treatment except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). A 1-week washout is permitted for palliative radiation(≤2 weeks of radiotherapy) to non-CNS disease.
- Had major surgery within 28 days of the first dose of study treatment. Minor surgical procedures are allowed.
- Has symptomatic brain metastasis or leptomeningeal disease. Prior brain metastasis or leptomeningeal disease allowed if asymptomatic or stable symptoms that did not require an increased dose of corticosteroids to control symptoms within 7 days prior to study enrollment. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or stereotactic radiosurgery treatment before enrollment and be clinically stable.
- Has current spinal cord compression
- Other malignancy within 3 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
- Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection
Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- Myocardial infarction within 6 months before the first dose of brigatinib.
- Unstable angina within 6 months before first dose of brigatinib.
- Congestive heart failure within 6 months before first dose of brigatinib.
- History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia).
- Any history of clinically significant ventricular arrhythmia.
- Has uncontrolled hypertension.
- Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose brigatinib.
- Have a history or the presence of pulmonary interstitial disease, drug-related pneumonitis, or radiation-related pneumonitis
- Active infection requiring systemic therapy.
- Known history of HIV infection.
- Has a known or suspected hypersensitivity to brigatinib or its excipients.
- Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug (if applicable).
- Have any condition or illness that, in the opinion of the investigator, would compromise
- patient safety or interfere with the evaluation of brigatinib
- Received systemic treatment with strong cytochrome P-450 (CYP)3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers within 14 days before enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brigatinib
Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily.
A Cycle will be defined as 28-days.
Treatment will be continued until disease progression or unacceptable toxicity.
|
Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily.
A Cycle will be defined as 28-days.
Treatment will be continued until disease progression or unacceptable toxicity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: From Cycle1 Day 1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. Tumor assessment will be performed at the end of cycle 2(every 2 cycles, each cycle is 28 days).
|
Objective response rate
|
From Cycle1 Day 1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. Tumor assessment will be performed at the end of cycle 2(every 2 cycles, each cycle is 28 days).
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC2019-0212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Genelux CorporationNewsoara Biopharma Co., Ltd.Not yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Clinical Trials on Brigatinib
-
TakedaWithdrawnSolid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
-
TakedaCompletedALK-positive Advanced NSCLCJapan
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
Fox Chase Cancer CenterWithdrawnAnaplastic Large Cell Lymphoma, ALK-PositiveUnited States
-
Fundación GECPActive, not recruitingNSCLC | Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIBSpain
-
Criterium, Inc.University of Colorado, Denver; Georgetown University; Takeda; University of Pittsburgh and other collaboratorsTerminatedNon-Small Cell Lung CancerUnited States
-
Ariad PharmaceuticalsNo longer availableCarcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced MalignanciesUnited States
-
TakedaRecruitingNon-small Cell Lung Cancer (NSCLC)Japan
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingNSCLC Stage IV | ALK Gene Mutation | ALK Sensitizing MutationItaly
-
TakedaRecruitingNon-small Cell Lung Cancer (NSCLC)China